Comparative Oncology and Clinical Translation of glyco protein conjugated Gold Nano Therapeutic Agent (GA-198AuNP) [abstract]
Kan, Para, 1980-
Cutler, Cathy S.
Jurisson, Silvia S. (Silvia Sabine)
Katti, Kavita K.
Axiak, Sandra M.
Lattimer, Jimmy C.
Henry, Carolyn J.
Volkert, Wynn A.
Ketring, Alan R.
Casteel, Stan W.
Katti, Kattesh V.
University of Missouri (System)
Metadata[+] Show full item record
As part of our efforts toward clinical translation of GA-198AuNP, our studies are focused on therapeutic efficacy of nanoparticulate GA198AuNP agent in dogs with prostatic carcinoma. The overall goal is to gain clinical insights on therapeutic efficacy of GA198AuNP in a large animal model. We have performed a phase I clinical trial using GA-AuNP administered intravenously or intratumorally by injection or infusion. CT scans were performed prior to injection and 24 hours post injection in 3 of the 4 dogs. Following injections, dogs were allowed further treatment as recommended by the primary attending clinician. Four dogs have been treated to date. Complications related to GA-AuNP treatment were not observed, and all 4 dogs received adjunctive treatment with radiation therapy and/ or chemotherapy. These preliminary studies have clearly provided compelling evidence on the therapeutic potential of biocompatible GA-AuNP for their utility as novel therapeutic agents in treating various types of inoperable solid tumors. Intra-tumoral and intravenous administration of GA-AuNP is safe in dogs with spontaneously occurring tumors. As further therapeutic efficacy studies continue, the outcome of this clinical trial in a large animal model will generate therapeutic efficacy data which will be used for filing IND application for Phase I clinical trial studies. This clinical translation effort provides significant advances in terms of delivering optimum therapeutic payloads into prostate cancers with subsequent reduction in tumor volume, thus may effectively reduce/eliminate the need for surgical resection. This presentation will include details of clinical translation of GA198AuNP in prostate tumor bearing dogs.
Abstracts (Missouri Regional Life Sciences Summit 2010)